Bellus Health Inc

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTA™, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

GlaxoSmithKline

BELLUS Health Inc (TSX:BLU) said its shareholders overwhelmingly have approved a US$2 billion takeover by GSK PLC (LSE:GSK, NYSE:GSK). The late-stage biopharmaceutical firm said in a statement that almost 100% of shareholders at a special meeting voted in favor of the US$14.75 per share offer.

Bellus Health shareholders say yes to US$2B GSK takeover

MONTREAL--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“BELLUS” or the “Company”) today announced the positive outcome of the BELLUS shareholders (“Shareholders”) vote at this morning's special meeting of the Shareholders (the “Special Meeting”) held in-person, approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the “Arrangement”) pursuant to which 14934792 Canada Inc. (the “Purchaser”), a corporation exi.

BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders

MONTREAL--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“BELLUS” or the “Company”) today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the “Special Meeting”) of shareholders of BELLUS (“Shareholders”) on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the “Arrangement Resolution”) approving the previ.

BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), today reported its financial and operating results for the quarter ended March 31, 2023. “Our merger agreement with GSK underscores our corporate and clinical achi.

BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights

After reaching an important support level, Bellus Health Inc. (BLU) could be a good stock pick from a technical perspective. BLU recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Should You Buy Bellus Health (BLU) After Golden Cross?

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), has announced the meeting and record dates for the special meeting of shareholders to be held in connection with the acquisition of the Company by GSK plc for US$2.

BELLUS Health Announces Meeting Updates

U.K.-based GSK is buying Canadian biotech Bellus Health for $2 billion. The purchase will include a promising drug candidate for treating chronic cough.

Was This Acquisition a Savvy Play by This Big Pharma Stock?

Bellus' lead therapy, camlipixant, is being tested against refractory chronic cough. The company is a clinical-stage biotech with no marketed therapies.

Why Shares of Bellus Health Skyrocketed This Week

Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.

Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK

11:55am: Bellus Health (TSX:BLU), The Lion Electric Company shares make big gains  BELLUS Health Inc (Bellus Health (TSX:BLU)) shares shot up 99% to $19.33 on Tuesday after the late-stage biopharmaceutical company announced that it has agreed to be acquired by GSK PLC (LSE:GSK, NYSE:GSK) for US$14.75 per share in cash.   As well, shares of The Lion Electric Company (TSX:LEV) shares continued to move higher Tuesday, up 19% to $3.13 following a 12% gain on Monday, as the manufacturer of all-electric medium and heavy-duty vehicles said it officially introduced its new manufacturing factory in Mirabel, Quebec, which will produce lithium-ion batteries for medium and heavy-duty vehicles.

Biopharma stock soars on takeover deal plus more daily small cap and micro cap movers

Shares of Bellus Health Inc (NASDAQ: BLU) almost doubled this morning after GSK plc (LON: GSK) said it will buy the biopharmaceutical company for about $2.0 billion. Details of the announced acquisition The all-cash agreement values Bellus Health shares at $14.75 that translates to more than a 100% premium on their previous close.

Biopharma stock Bellus Health almost doubled today: find out why

LONDON--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion (£1.6 billion).

GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

BELLUS Health and GSK have agreed on a $2 billion buyout agreement. Through this deal, GSK will acquire a late-stage chronic cough medication that could be worth billions in peak sales.

Why BELLUS Health Stock Is Rocketing Higher Today

GSK added to a series of recent takeovers Tuesday with the $2 billion acquisition of Bellus Health. But BLU stock and GSK stock diverged.

Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal

Goldman Sachs

Here are some of the biggest movers on Tuesday:

Bellus Health's stock climbs on GSK deal, while Goldman Sachs is hurt by a revenue miss

Bellus Health (NASDAQ: BLU ) stock is taking off on Tuesday after the company announced an acquisition deal with GSK (NYSE: GSK ). GSK has agreed to acquire Bellus Health for $2 billion.

Why Is Bellus Health (BLU) Stock Up 98% Today?

GSK PLC (LSE:GSK, NYSE:GSK) has paid around £1.6bn for Bellus Health (TSX:BLU) Inc, a Canada-based, late-stage biopharmaceutical company which specialises in respiratory treatments. The pharmaceuticals giant said the deal further strengthens specialty its medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough.

GSK pays £1.6bn for Canada's Bellus Health

GSK PLC said Tuesday that it has reached an agreement to buy the late-stage biopharmaceutical company Bellus Health Inc. BLU, +3.08% BLU, +2.83% for $14.75 a share in cash, representing a total equity value of around $2.0 billion.

GSK to acquire U.S.-based BELLUS Health for $14.75 per share

Bellus (BLU) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Bellus (BLU) is Poised for a Turnaround After Losing -15.33% in 4 Weeks

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc.

BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation

The mean of analysts' price targets for Bellus (BLU) points to a 156% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Bellus (BLU) Could Surge 156.01%: Read This Before Placing a Bet

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), today reported its financial and operating results for the year ended December 31, 2022.

BELLUS Health Reports Year 2022 Financial Results and Business Highlights

BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference

BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting

Refractory chronic cough remains as a complex condition that requires a medical breakthrough for treatment. BELLUS Health Inc. is pushing ahead on this front, with recent support from evidence in its recent clinical trials.

News for Bellus Health Inc Stock (BLU)